




Ajinomoto Co., Inc. (2802)

Forecast for FY2023 (Ending March 31, 2024) and Initiatives for Enhancing Corporate Value

Taro Fujie

Director, Representative Executive Officer, President & Chief Executive Officer

November 6, 2023





3

Message from the CEO

- FY23 first half sales and business profit both set new records; FY23 revised forecasts for sales
 and business profit are maintained from the initial forecast, while profit attributable to owners of
 the parent company is revised upward to 100 billion yen.
- Profit margin has recovered significantly in Seasonings and Foods overseas, and the results of structural reform have become apparent in Frozen Foods in North America. This is mainly due to our quick actions (price changes) in FY2022 being successful.
- We raised unit prices and wanted to bring the quantities of Seasonings and Foods in Japan back to what they had been, but we weren't able to due to consumers' reactions to protect their lifestyles against increased costs.

We established Marketing Design Center and the ground to stand ready at bat (to launch new products) is just about done. We will take short-term and medium- to long-term actions solidly in place.

- A slower-than-expected recovery in the semiconductor market and inventory adjustments by clients that were greater than expected affected the performance of Healthcare and Others. However, the market is growing, and we are confident of a return to growth.
- The company is promoting the 2030 Roadmap working to enhance its corporate value by and continuing to refine it.
- Short-term measures are necessary for FY2024. By also promoting initiatives to lower the breakeven point (concentration and reduction of SKUs, etc.), the company will steadily achieve FY2023 targets and double-digit growth in business profit for FY2024 in line with the roadmap. Copyright © 2023 Ajinomoto Co., Inc. All rights reserved



Sales: Increased (New first-half record) ¥688.0 billion 104.3% of FY2022				s profit: Increased	Profit attributable to owners of the parent company				
			¥	76.5 billion	¥46.4 billion 98.7% of FY2022				
			10	03.0% of FY2022					
Excluding currency tra	nslation: 100).8%	Excluding	currency translation: 98.8%					
up ¥28.1	billion		up ¥	2.2 billion					
The increase in Seas Foods, and Frozen F the decrease in Heal Others.	oods covere	ed	and Foods, a overseas, wi	sed primarily in Seasonings and Frozen Foods, both th currency translation also offsetting the decrease in and Others.					
YoY Business Profit Detai	ls – Summa	ry							
(¥ Billion)	vs Q1-FY22	vs Q2-FY22	vs H1-FY22	Details of impacts in H1-FY23					
Change in GP due to change in sales	6.5	3.5	10.0	The increase in revenue in overseas Seasonings and Foods and overseas Frozen Foods exceeded the decrease in revenue in Healthcare and Others					
Change in GP due to change in GP margin	0.0	0.7	0.7	Improvement of the GP margin in overseas Seasonings and Foods and overseas Frozen Foods offset the GP margin decline in Healthcare and Others					
Change in SGA expenses	-2.7	-4.2	-7.0	SGA expenses increased due to	advertising and R&D investments in line with strate				
		0.0	-1.4						
Share of profit of associates and joint ventures	-1.4	0.0	-1.4						


I would like to discuss our results for the first half of the fiscal year ending March 2024. In the first-half results for fiscal 2023, we achieved record sales and business profit.

Sales reached 688 billion yen. This was 104.3% the level of the previous year, or 100.8% with the effects of currency translation excluded.

The increase in revenue in Seasonings and Foods and in Frozen Foods, in which we've engaged in price increases and other initiatives since the previous fiscal year, covered decreased revenue in Healthcare and Others, resulting in increased revenue overall.

Business profit was 76.5 billion yen, 103.0% the level of the previous year.

Excluding the effects of currency translation, business profit was 98.8% the level of the previous year. Excluding accounting-related and other transient effects at overseas affiliates accounted for by the equity method, we effectively secured performance exceeding that of the previous year.



This slide shows an analysis of the difference in business profit between the first half of fiscal 2022 and the first half of fiscal 2023.


Change in GP due to change in sales was +10 billion yen compared to the same period last year, with contribution from price increases both overseas and in Japan.

Although the change in GP due to change in GP margin was significantly positive in food-related businesses, it was negative in Healthcare and Others. The increase overall was 700 million yen. Profit increase due to unit price growth in Seasonings and Foods and Frozen Foods was large, which countered the 8 billion yen gross cost impact of raw materials and fuels, covering the negative results in the Healthcare and Others segment.

In SGA, we are expanding necessary intangible asset investments for future sustainable growth, in line with our 2030 Roadmap strategy.

In the second half, we plan to achieve further increases in revenue and profit in the consumer foods business by raising unit prices and steadily increasing volume.

While making necessary investments, we will work to achieve double-digit percentage growth in business profit.




This slide shows an analysis of difference in business profit by segment for the first half of fiscal 2023, compared to the same period in the previous year.

For reference, at the bottom of the slide is an analysis of the difference between the full-year forecast at the start of the fiscal year and performance in the previous fiscal year.

You can see that, compared to the full-year forecast at the start of the fiscal year, we achieved very strong profit growth in Seasonings and Foods and Frozen Foods, which have already greatly exceeded the full-year increase in profit forecasted at the start of the fiscal year.

In Healthcare and Others, profit in the first half of fiscal 2023 was significantly lower than the profit increase forecasted for the full year at the start of the fiscal year. I will discuss the reasons later.




For combined Sauces and Seasonings and Quick Nourishment in Japan and overseas, this slide breaks down sales into volume and unit price, and also shows an analysis of change in business profit.

For the first half of fiscal 2023, sales in Japan were 103% the level of the previous year. Broken down, volume was 98% and unit price was 106% the level of the previous year. Volume declined in response to price increases in soups and coffee and due to a shift away from a mindset of guarding lifestyles and toward some private brand products under a low-cost orientation, mainly in Sauce and Seasonings. As a result, volume declined from the previous year.

The waterfall chart at bottom left shows that the effect of unit price increases was unable to cover the increase in manufacturing costs caused by higher raw material costs and lower volume, resulting in a decline in profit.


By contrast, overseas we achieved double-digit percentage growth in sales on a local currency basis by increasing unit prices to 109% the level of the previous year primarily through price revisions, while steadily increasing volume to 101%.

In terms of business profit, too, we largely countered the increase in costs associated with raw material and fuel price inflation, resulting in increased profit.



We conducted a review of our performance forecast for fiscal 2023. We aim to achieve company-wide sales and business profit in line with our initial targets. At the same time, we are scrutinizing current conditions and estimates by segment and are revising the forecast.


In addition, we revised operating profit and other profit upward to reflect factors including the contract for the sale of the former factory site of Ajinomoto (Malaysia) Berhad, which we reported as a subsequent event in August.



This slide shows a business profit waterfall chart for the revised forecast.

The increase in unit prices for the domestic and overseas consumer businesses in excess of our initial forecast for the fiscal year, and GP growth due to volume growth exceeding the first half, will cover decline in GP due to decreased revenue in Healthcare and Others.


We will carry out investments for the future as scheduled and will work to solidly achieve business profit of 150 billion yen.



This slide shows an analysis of the difference in business profit between the previous year's results and the initial forecast for the fiscal year, by segment in the revised forecast.

Adding in the increased profit from the previous fiscal year in Seasonings and Foods and in Frozen Foods, resulted in a significant upward revision from the initial forecast.


By contrast, the lower graph shows a downward revision in Healthcare and Others, mainly in Functional Materials and in Bio-Pharma Services & Ingredients. We expect profit to decrease from the previous year.



For combined sauce and Seasonings and Quick Nourishment in Japan and overseas in the revised forecast, this slide breaks down sales into volume and unit price, and also shows an analysis of change in business profit.

We plan for sales in Japan to be 108% the level of the previous year, breaking down to 100% by volume and 108% by unit price. We expect volume to recover due to factors including the effect of new product launches, but we have made a revision from 103% in the initial forecast to 100%.


Overseas, we plan for growth in excess of the initial forecast, with volume of 103% and unit price of 108% the levels of the previous year. As a result, we expect double-digit percentage growth in sales.



Next is Frozen Foods.

In Frozen Foods in North America, structural reform including portfolio reform and initiatives for Operational Excellence (OE) in a project to expand Total Delivered Cost (TDC) margin (including last year's price increases) is yielding effect, and we achieved significant increase in profit.


While continuing reform through fiscal 2025, we will steadily generate results from our structural reform and will strengthen the foundation for subsequent dramatic growth.



In ABF, we revised sales and profit downward from the initial forecast for the fiscal year due to delayed recovery in the semiconductor market.

The use of generative AI has come under considerable attention in recent years. Semiconductors for AI, which still account for a small proportion of the semiconductor market, are expected to grow dramatically. In terms of both area and number of layers, a greater amount of ABF is used in GPU substrates for AI than in substrates for standard PCs.

Combined with recovery in the semiconductor market overall, the advance of generative AI is another element that will accelerate growth for ABF.



Next is Bio-Pharma Services & Ingredients.


First, I will look at amino acids for pharmaceuticals and foods.

In the first half of fiscal 2023, greater-than-expected inventory adjustment by customers had a major impact on sales and profit.

In relatively high-profit amino acids for biopharmaceuticals in particular, customers' speed of inventory adjustment was fast and the impact on profit was also large.

The biopharmaceuticals market is growing steadily, and we expect recovery in the second half when inventory adjustment runs its course.

Unfortunately, the second half on its own will not be able to cover the initial forecast for the fiscal year, so we have revised full-year sales and profit downward to reflect the decline in the first half.




This slide looks at Bio-Pharma Services.

In Bio-Pharma Services, first-half profit decreased from the same period in the previous year due to impacts of inventory adjustment by customers, mainly in biopharmaceuticals in North America, and due to conversion of some equipment to nucleic acid-based drug manufacturing in Europe.

Conversely, nucleic acid-based drug CDMO services, a driver of growth, are performing well, with sales in the tens of billions of yen annually. We expect growth in fiscal 2023 to be 120% the level of the previous year.

By building a new production base in Europe, we will achieve sustainable growth for CDMO services overall to meet robust global demand.




This slide shows progress in ASV indicators under the 2030 Roadmap.


Regarding ROE and ROIC, we have revised our initial forecast upward and will aim to achieve the revised forecast for fiscal 2023 in order to achieve the 2030 ASV indicators.

Segment	Organic growth				Business profit			ROIC		EBITDA margin				
		Vs.	prev. year	CAGR		Vs.	prev. year	CAGR						
Sauce & Seasonings	FY22 actual (sales)	H1- FY23	FY23 (revised forecast)		FY22 actual (BP)	H1- FY23			actual (revis	ed (FY22-25)	FY22 actual	H1- FY23		
Quick Nourishment	¥775.0	5.3%	6.8%	5%	¥84.8	29.8%	24.7%	12%	15.9% 199 Appro	% * 16%	14.9%	18.2%	Approx.	16%
Solution & Ingredients	Dillion				billion									
Frozen Foods	¥267.2	2.3%	4.8%	3%	¥2.0	¥6.6	¥10.0	billion	1 10		5.5%	9.6%	Approx. 8%	8%
						Dimon	Dillon	or more		5%				
Bio-Pharma Services & Ingredients									Appre	,			Annew	
Functional Materials (electronic materials and others)	¥299.6	-11.9 %	-3.4%	8%	¥48.6 billion	-62%	-27%	13%			21.8%	14.5%		279
Others									WACC	7%				
	¥1.359.1		4.1%	5%	¥135.3		10.8%	150	9.9% 10.0	% 13%	15.2%			
	Sauce & Seasonings Quick Nourishment Solution & Ingredients Frozen Foods Bio-Pharma Services & Ingredients Functional Materials (electronic materials and others)	Sauce & Seasonings FY22 actual (sales) Quick Nourishment ¥775.0. Solution & Ingredients ¥175.0. Frozen Foods ¥267.2. Bio-Pharma Services & Ingredients ¥267.2. Bio-Pharma Services & Ingredients ¥299.6. Functional Materials (electronic materials and others) ¥299.6.	Sauce & Seasonings FY22 seasonings H- actual scalar (sides) Quick Nourishment Solution & Ingredients ¥775.0 billion 5.3% Frozen Foods ¥267.2 billion 2.3% Bio-Pharma Services & Ingredients ¥299.6 Site of the second billion -11.3 billion Functional Materials (detectronic materials and others) ¥299.6 Site of the second billion -11.3 Site of the second Site of the second billion	Va prev. year Sauce & Seasonings Quick Nourishment With Provided forecast) Quick Nourishment Solution & Ingredients Frozen Foods W267.2 Bio-Pharma Services & Ingredients Functional Materials (detectoric materials and others)	Vs. prev. year CAGR Sauce & Seasonings FY22 (sales) FY23 (revised (FY22.25) (revised (FY22.25) forecast) Quick Nourishment F775.0 5.3% 6.8% 5% Solution & Ingredients Frozen Foods F22.2.3% 4.8% 3% Bio-Pharma Services & Ingredients ¥267.2 2.3% 4.8% 3% Bio-Pharma Services & Ingredients ¥299.6 -11.9 % -3.4% 8%	Vs. prev. year CAGR Sauce & Seasonings FY22 actual (sales) FY23 F722 forecast) FY23 forecast) FY22 actual (BP) Quick Nourishment ¥775.0 billion 5.3% 6.8% 5% ¥84.8 billion Solution & Ingredients ¥267.2 billion 2.3% 4.8% 3% ¥2.0 billion Bio-Pharma Services & Ingredients ¥269.6 billion -11.9 % -3.4% 8% ¥48.6 billion Globerts ¥299.6 % -11.9 % -3.4% 8% ¥48.6	Vs. prev. year CAGR FY23 FY24 FY24 FY24 FY24 FY24							


ASV indicators for each segment are as shown here.




In fiscal 2023, we expect inventories to increase from the initial forecast due to the effects of currency translation. We have revised the forecast for net D/E ratio downward to slightly below the 30% to 50% range .



We revised operating cash flow downward from the initial forecast for reasons including the effects of currency translation, but we will achieve cash generation in excess of the previous fiscal year.




We will move forward with necessary investments in tangible and intangible assets as planned.




This slide shows important management indicators in the Purpose-Driven Management by Medium-Term ASV Initiatives 2030 Roadmap.

We have revised ROE, ROIC, and EPS upward.



In fiscal 2023, we aim to generate 160 billion yen in cash, and have already bought back shares worth 50 billion yen.



I would like to talk about shareholder returns.

We plan no dividend decrease, and instead plan to increase the annual dividend by 6 yen in fiscal 2023 to 74 yen by paying dividends based on a progressive dividend policy of increasing or maintaining dividends and based on normalized EPS that is less susceptible to non-routine gains and losses.

We bought back 9.6 million shares valued at 50 billion yen in the first half. We will continue working to strengthen our shareholder returns.





Over half a year has passed since we announced the Purpose-Driven Management by Medium-Term ASV Initiatives 2030 Roadmap at the end of February this year.

Since September, we have engaged in Roadmap Follow-up meetings with business departments, laboratories, sales teams, overseas affiliates, and more.

We hold meetings not only to check current progress but also to evolve the Roadmap, through discussions on topics such as the inability to "reach Everest" in 2030 despite good progress if we merely extend current targets, whether people, goods, or money are insufficient for attaining heights in 2030, and requests for pushing top management to invest in certain businesses to achieve goals.

The management team continues to increasingly head into the field to engage in further dialogue. We are also solidly pushing the goals of "visualization," "sowing seeds for the future," and "investment in intangible assets."




I would like to show a scene from a Roadmap Follow-up meeting.

Please watch this video of a meeting with the Marketing Design Center (MDC), which was established in April this year.

As Okamoto says in the video, we have launched measures and are undertaking initiatives to return the B-to-C food products business in Japan to growth.


While not shown in the video, we are also having solid discussions on overseas expansion of the MDC and are evolving the Roadmap toward 2030.

We are holding such Roadmap Follow-up meetings with numerous departments, including in overseas affiliates.



While engaging in a variety of initiatives, we may feel that some area has demonstrated ability, or conversely, that something needs further polishing and a renewed effort.

Today, I would like to introduce areas that have demonstrated ability and things that still need polish.




As we engage in varied businesses in many regions, some of these businesses face challenging situations.

I feel that we have increased in ability to address companies where performance has declined.

First, there is the recovery of performance in Vietnam.

There have been concerns about Vietnam, where we have lost considerable share to global giants in flavor seasonings as well as to the emergence of local competitors. From last fiscal year, however, recovery in performance has been remarkable.


With involvement by the Head Office, we launched a revival plan by the regional headquarters and affiliates, appointed a new president, and worked to reform the organizational culture. By increasing the speed of decision-making and by solidly making KPIs visual, we boosted the share of our main brands and are achieving recovery in sales and profit.



Another matter I mentioned earlier is recovery of performance in Frozen Foods in North America. The COVID-19 pandemic and inflation surged during structural reform, and at one point the business fell into deficit. While tracking progress in monthly Executive Committee meetings, we also advanced recovery initiatives together with affiliates and are now seeing recovery in performance.


Next, General Manager Sakakura of the ASEAN Division will explain the Division's initiatives, centered on rolling forecasts.

Mr. Sakakura, if you would.



This is Sakakura. I would like to introduced initiatives undertaken at the ASEAN level. The current status of ASEAN is now supported by the rolling focus initiatives that we have implemented in 2021. These are now taking root inside our entire organization. From 2020, we started on a test basis in Indonesia. Based on that, from 2021, we have expanded the rollout to eight countries in the ASEAN region. The reason why we have implemented this is because back then, at ASEAN countries, I was astonished by the fast-changing environment. We also thought that the slow response of our company was a challenge for that. So, we wanted to capture the signs of changes as quickly as possible and respond quickly, and that's the reason why we have introduced a rolling forecast. Early detection and early cure were the major purpose here.

By looking at the changes and the gap with the forecast on a monthly basis, we are able to identify what's the reason behind the gap. Also, by looking at the YoY changes of the gap, we are looking into the feasibility and be able to forecast the changes between the full-year gap and also the market basis and reduce the expenses as necessary and also revise the prices as an additional price revision. For the raw materials, currently from each company, the impact on the performance of the Company in terms of the scale of such impact, we are now looking into and monitoring 20 items. Not only PL, but the CCC indicators has also taken monitoring so that we can lead this to the next action. So, through these actions, based on that, from 2023, we have started the rolling forecast initiatives on a global basis.



The rolling forecast, besides early detection and early cure, this also has an impact of management quality improvement because this will have a full management change impact. This is a very huge impact.

The changes with the sales forecast could have an impact on the sales and also the cost plan, and this will have an impact on the CCC and the performance. This will be visualized. Also, the marketing initiatives and the product development delay could have an impact on the sales plan. Of course, that will have a negative or positive impact on the performance of the Company.

Of course, it may consider to be a matter for granted. But of course, visualization of this will further enhance the collaboration within the organization. This also leads to the improvement of the management quality. In reality, we believe the management quality has enhanced as a result of this measure. Of course, there were many trials and errors over the last two years. And of course, there are still management issues to be perfected. but I think we can say that we were able to establish a format that will enhance the management capability.




The ability to read and forecast and also the management capabilities. What we have implemented in ASEAN, for example, the raw material and the fuel cost, we are able to identify these and also the competitors' move so these are reflected swiftly into the price changes of our product and the wellbeing of people and the well-being of earth. We were able to launch these new products that are contributing to the well-being of the people and earth. Of course, the flavor seasoning and also the reduced food were the good examples of that. Also, the post-COVID-19 environment, the people liquidity hasn't [inaudible] as a result of COVID-19 so the HR market, we have to review the talent system, the human resource system, that is catered to the current market and we were able to take immediate actions towards that direction.



These are the items to be executed or to be expanded horizontally. Let me introduce some of them. First, by utilizing the strength of both food and AminoScience, in Thailand, for example, on the righthand side, Amino MOF is a product name. This is for the elderly supplement. In November, we launched this product in Thailand. In Vietnam, to improve mother-and-child nutrition, in collaboration with the government, mother and children project has been kicked off. In Vietnam, the school lunch or school meal project has been launched already. As a continuation, in line with the government or collaboration with the government, by utilizing our intangible assets, we are launching new projects.

Thailand has also started an EC project with an external collaborator that has been expanded to ASEAN nations. The EC has been conducted on our own but by inviting external experts. As a result, we were able to actually expand the profit of EC market in Thailand.

Lastly, there are areas where existing businesses cannot address slightly different from the existing product lineup, and this could be a potential hit. Therefore, we need to make sure that we can harness this new value creation or new business creation. There is a specific team dedicated for creating a new business leading to a further new value creation, and we are accelerating this special project as well.



Thank you very much, Mr. Sakakura.

I would like to introduce initiatives that still need polish. The first is the reduction of inventories.


Amid disruption of supply chains due to the pandemic and the Ukraine crisis, we focused on delivering products punctually and held on to greater inventory than usual.

As supply chains is normalize following the pandemic, we will steadily reduce inventories by advancing visualization and other initiatives while checking progress.

In the short term, we will promote centralization and reduction of SKUs, lower our break-even points, and evolve toward a lean structure.

Our price increase initiatives in the previous fiscal year, especially in the foods sector, are greatly contributing to lifting performance this year.

Heading into the next fiscal year, too, we will solidly lower our break-even points through concentration and reduction of SKUs, and will speed up initiatives, particularly those aimed at boosting profits and further improving our financial structure.



Next is intangible assets, particularly the human assets that are the source of innovation.


Preliminary results of this fiscal year's engagement survey have come out. The ASV realization process that we introduced in the previous fiscal year rose by 1 point to 76 points.

The ASV realization process consists of the eight elements described here. While we have maintained a high score for most items, it can be seen that the score for "Enhancement of productivity" is very low, bringing the overall score down.

Looking into the reasons for the low score of this item, we found that one factor is our culture of behind-the-scenes consensus-building, with many internal approval procedures.


We are trying to break away from this culture through means including promoting proactive participation in volunteering. Last year's score improved.

The score is still low, however, so we will promote reform of awareness through means including network-oriented work-style measures that cross the boundaries of assigned work through volunteering.



Regarding the relationship between engagement surveys and performance, we are currently analyzing the fiscal 2023 engagement survey.

We will disclose results to you when they are ready.




Within human assets, a particular challenge we face is the growth environment and career development for employees in their 20s.

The score among this age group has improved in the engagement survey but remains low compared to the whole. Our score for "growth environment for employees in their 20s" from OpenWork also shows a need for improvement.

Envisioned issues include:

- · Few opportunities for active work and growth in one's 20s
- · Unable to envision a career

These are issues that we will tackle.



To increase opportunities for growth and active roles by young employees, we are advancing programs for new business creation and recruitment of human resources.

We are further enriching information on career design and are also providing coaching training for all managers who guide young employees, and are developing structures to support the growth of young employees.

We view active participation by young employees as a driving force for growth of the company, and will pursue the realization of ASV together with all employees.




Message from the CEO (Reposted) FY23 first half sales and business profit both set new records; FY23 revised forecasts for sales and business profit are maintained from the initial forecast, while profit attributable to owners of the parent company is revised upward to 100 billion yen. Profit margin has recovered significantly in Seasonings and Foods overseas, and the results of structural reform have become apparent in Frozen Foods in North America. This is mainly due to our quick actions (price changes) in FY2022 being successful. We raised unit prices and wanted to bring the quantities of Seasonings and Foods in Japan back to what they had been, but we weren't able to due to consumers' reactions to protect their lifestyles against increased costs. We established Marketing Design Center and the ground to stand ready at bat (to launch new products) is just about done. We will take short-term and medium- to long-term actions solidly in place. A slower-than-expected recovery in the semiconductor market and inventory adjustments by clients that were greater than expected affected the performance of Healthcare and Others. However, the market is growing, and we are confident of a return to growth. The company is promoting the 2030 Roadmap working to enhance its corporate value by and continuing to refine it. Short-term measures are necessary for FY2024. By also promoting initiatives to lower the breakeven point (concentration and reduction of SKUs, etc.), the company will steadily achieve FY2023 targets and double-digit growth in business profit in line with the roadmap for FY2024. Copyright © 2023 Ajinomoto Co., Inc. All rights reserved 40

I am reposting the message that I presented at the beginning.

We will promote the enhancement of our corporate value so that we can achieve our fiscal 2023 targets and present performance in line with the Roadmap in fiscal 2024.

Thank you for your time today.



Sales: Increased		Business profit: Decreased	Profit attributable to owners of the parent company		
¥348.4 billion		¥33.7 billion	¥ 19.2 billion		
103.0% of FY2022		99.7% of FY2022 99.7% of FY2022			
Excluding currency translation:	99.4%	Excluding currency translation: 94.9%			
Increased overall, led by Seasonings and Foods and Frozen Foods. YoY Business Profit Details		Although profit increased mainly in Seasonings and Foods, and Frozen Foods, both overseas, it could not cover for the decrease in profit in Healthcare and Others.			
oY Business Profit Detail	S				
	s vs Q2-FY22	Details of impact	s in Q2		
(¥ Billion) Change in GP due to	/s Q2-FY22				
(¥ Billion) Change in GP due to change in sales Change in GP due to	/s Q2-FY22 3.5	Details of impact	and overseas Frozen Foods exceeded the		
(¥ Billion) Change in GP due to change in sales	/s Q2-FY22 3.5 0.7 1 d	Details of impact The increase in revenue in verseas Seasonings and Foods lecrease in revenue in Healthcare and Others The improvement in GP margin in overseas Seasonings and	and overseas Frozen Foods exceeded the Foods and overseas Frozen Foods offset th		

Aj Aj

Forecast (Consolidated Statements of Income)

(¥ Billion)	FY23 revised forecast (A)	FY23 initial forecast (B)	Difference (A)-(B)	FY22 actual (C)	Difference vs. prev. year (A)-(C)	
Sales	1,465.0	1,465.0	0.0	1,359.1	105.8	
Business profit	150.0	150.0	0.0	135.3	14.6	
Other operating income & expenses	3.0	-6.0	9.0	13.6	-10.5	
Operating profit	153.0	144.0	9.0	148.9	4.	
Financial income & expenses	-2.0	-5.0	3.0	-8.9	6.8	
Profit before income taxes	151.0	139.0	12.0	140.0	10.9	
Income taxes (Tax rate: FY23 revised forecast 25.8%)	-39.0	-37.8	-1.2	-39.8	0.8	
Profit (includes discontinued operations)	112.0	101.2	10.8	100.1	11.8	
Profit attributable to owners of the parent company	100.0	95.0	5.0	94.0	5.9	
Profit attributable to non- controlling interests	12.0	6.2	5.8	6.1	5.8	

Copyright © 2023 Ajinomoto Co., Inc. All rights reserved

43

ssumed						
	exchange rate	s (vs. JP	Y)			
	FY23			actual		FY23
USD	revised forecast		Q3	Q2 144.63	Q1	initial forecast
050	143.00			144.63	137.49	135.00
EUR	156.00			157.32	149.58	135.00
тнв	4.07			4.11	3.99	3.75
BRL	28.85			29.59	27.81	25.96
0	Rate Sensitivi nange rates (vs. JP FY23 revised forecast	Y) Sensitivity	of translation ear business			
•	nange rates (vs. JP FY23	Y) Sensitivity (on full ye		profit		
oreign excl	nange rates (vs. JP FY23 revised forecast	YY) Sensitivity o on full ye ±¥1 → ap	ear business	nillion		
oreign excl	nange rates (vs. JP FY23 revised forecast 143.00	YY) Sensitivity o on full ye ±¥1 → ap ±¥1 → a	ear business pprox. ¥100 r	nillion		

:	Segment	Orga	nic gro	owth	Bus	iness	profit		ROIC		EBITDA margin		
			Vs. prev. year	CAGR		Vs. prev. year	CAGR						
	Sauce & Seasonings	FY22 actual (Sales)	FY23 initial forecast	FY25 plan (FY22-25)	FY22 actual (BP)	FY23 initial forecast	FY25 plan (FY22-25)	FY22 actual	FY23 initial forecast	FY25 plan	FY22 actual	FY23 initial Forecast	FY25 plan
Seasonings and Foods	Quick Nourishment	¥775.0 billion	7.4%	5%	¥84.8 billion	9.6%	12%	15.9% *11.8%	Approx. 14%	16%	14.9%	Approx. 15%	16%
	Solution & Ingredients								WACC 7%				
Frozen Foods	Frozen Foods	¥267.2	10.0%	3%	¥2.0	¥3.7	¥10.0 billion	-3.3% *0.6%	Approx. 1%	5%	5.5%	Approx. 6%	8%
Foous		billion			billion	billion	or more		WACC 5%			0.70	
Healthcare and Others	Bio-Pharma Services & Ingredients Functional Materials (electronic materials and others) Others	¥299.6 billion	11.4%	8%	¥48.6 billion	11.3%	13%	12.2%	Approx. 13% WACC 7%	18%	21.8%	Approx. 22%	27%
Total		¥1,359.1 billion	8.8%	5%	¥135.3 billion	10.8%	15% or more	9.9%	9.5% WACC 6%	13%	15.2%	15.4%	17%



Human Resource Initiatives (Receipt of the HR Award 2023)

In recognition of our comprehensive initiatives centered on measures to encourage autonomous changes in behavior by young employees, we received the Award for Excellence in the Corporate HR category at HR Awards 2023 of the Nihon no Jinjibu (sponsored by the HR Award Steering Committee, supported by the Ministry of Health, Labour and Welfare).



Copyright © 2023 Ajinomoto Co., Inc. All rights reserved

Glossary①		<i>⊲</i> IJINOMOT			
Term	Meaning and details	Page			
"AminoScience"	A collective term for the materials, features, technologies, and services obtained from research processes and implementation processes dedicated to the functions of amino acids.				
	"AminoScience" is also the Ajinomoto Group's unique scientific approach that connects those obtained qualities to solving social issues and contributing to well-being.				
Nucleic acid-based drugs	Drugs composed of a basic structure of nucleotides, the constituent components of the deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) that are responsible for the genetic information in organisms. Nucleic acid-based drugs are considered a third type of drug after small-molecule drugs and therapeutic antibodies, and may hold cures for diseases that	16			
	resist treatment with conventional drugs. Category management covers actions including the planning of strategies and				
Category management Brand management	management of profitability by product category. Brand management covers actions including the planning of strategies and management of profitability by brand. As an example, in North American Frozen Foods, "gyoza" is a category and "TaiPei" and "LingLing" are brands. More than brand management, category management enables	13•30			
Channel management	strategic planning and profitability management that are optimal overall. The planning of strategies and management of profitability by form of distribution, such as supermarkets, drug stores, and e-commerce.	13•31			
Biosimilars	Drugs with the same efficacy and safety as preceding biopharmaceuticals from other pharmaceutical companies, produced following expiration of the patents of the latter.	15			
Value chain	The flow of steps by which value is added in raw material procurement, manufacturing, shipping and transport, marketing, sales to customers (consumers), after-sales service, etc., until products and services reach customers.	13•28•30•32			
Material issues	Matters that are important to the Ajinomoto Group.	28			
Rolling forecast	A forecasting method by which future performance forecasts are continuously updated based on recent results, the external environment, and business plans. It is used to quickly and accurately draft and execute action plans for achieving short-term targets (performance forecasts) and medium-to long-term targets (ASV indicators).	28 · 31 · 32			

Glossary②		<i>₀</i> ¶J I NOMOT
Term	Meaning and details	Page
Number of days' sales in inventory (days inventory outstanding, DIO)	A value that expresses the number of days required for turnover of the inventory in question, i.e., the time taken to sell a product after stocking it. It is calculated as ((value of inventory at the beginning of the period + value of inventory at the end of the period) \div 2) \div cost of sales (annual) × 365 (number of days). Shortening of DIO relates directly to shortening of CCC and increases ability to generate cash.	32•35
Progressive dividend policy	A policy of increasing or maintaining dividends without reduction.	24
Single strand (antisense)	A single strand of DNA or RNA that inhibits or controls the functioning of its target by binding to the target's nucleic acid. Unlike DNA, RNA mostly exists as single strands. (As the main role of RNA is to copy the DNA blueprint temporarily, DNA-like double strands are thought to be unnecessary.) This is also the original target area of our original <i>AJIPHASE</i> ® technology.	16
Double strand (siRNA)	Short (about 20 bases in length), two-stranded RNA. siRNA is an abbreviation for short interfering RNA. siRNA works with proteins to regulate gene expression. It has been added to the target area of our original <i>AJIPHASE</i> ® technology through evolution of the technology.	16
AI and natural language AI	An abbreviation for artificial intelligence, Al technology allows computers to engage in reasoning, recognizing and understanding human speech, and other intellectual behaviors. Natural language Al refers to Al on a computer that processes everyday written and spoken languages such as Japanese or English, as opposed to artificial languages such as programming languages.	14
AJIPHASE®	Our company's original technology for oligonucleotide and peptide synthesis using liquid-	16
B-to-C	An abbreviation for business-to-consumer, this refers to business for the home market, aimed at general consumers.	28
CAGR	An abbreviation for compound annual growth rate.	17 · 18 · 45

Glossar	y 🥹	BINOMOTO
Term	Meaning and details	Page
ccc	An abbreviation for cash conversion cycle, a financial indicator that expresses the number of days required to recover trade receivables after payment of trade payables. It is calculated as the number of days for turnover of trade receivables + number of days' sales in inventories - number of days for turnover of trade payables. Shortening CCC enhances the ability to generate cash, which can be directed toward future investments and shareholder returns.	28 · 31 · 32
CDMO	An abbreviation for contract development and manufacturing organization, a party that develops and manufactures drugs under contract. A CDMO provides comprehensive services for manufacturing and development, such as contract drug manufacturing for pharmaceutical companies and optimization of manufacturing conditions during the development stage. A CDMO's scope of business is broader than that of a drug contract manufacturing organization (CMO) in that it can also take part in the development of investigational new drugs, such as the formulation process.	16
GP	Gross profit, calculated as sales - cost of sales.	5•6•10• 31•42
OE	An abbreviation for operational excellence, a state by which business operational advantages are maintained through efforts to enhance the efficiency of operations.	13•30
SKU	An abbreviation for stock keeping unit, the minimum unit of inventory management. As an example, under the same brand and same variety, "Cook Do® Twice-Cooked Pork" and "Cook Do® Twice-Cooked Pork, 2 Servings" make up two SKUs.	3•13•35•40
ГDC	An abbreviation for total delivered cost, the total cost of delivering products to their destination, calculated as the sum of costs of sales and logistics costs.	13•29•30
WACC	An abbreviation for weighted average cost of capital. Return on invested capital (ROIC), which expresses the earning power of a company, in excess of WACC leads to growth in corporate value.	18•23•45
Well-being	The state of being healthy and happy.	26•46

Reference Links



Ajinomoto Group IR Information https://www.ajinomoto.co.jp/company/en/ir/

Ajinomoto Group ASV Report (Integrated Report) 2023 https://www.ajinomoto.co.jp/company/en/ir/library/annual.html

Ajinomoto Group Medium-Term ASV Initiatives https://www.ajinomoto.co.jp/company/en/ir/event/medium_term.html

Ajinomoto Group Business Briefing / IR Day https://www.ajinomoto.co.jp/company/en/ir/event/business_briefing.html

Ajinomoto Group Stories https://www.ajinomoto.com/stories

Copyright © 2023 Ajinomoto Co., Inc. All rights reserved

50